Craig Hallum initiated coverage on Indivior with a new price target
$INDV
Biotechnology: Pharmaceutical Preparations
Health Care
Craig Hallum initiated coverage of Indivior with a rating of Buy and set a new price target of $37.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/6/2025 | $27.00 | Buy | H.C. Wainwright |
| 7/22/2025 | $20.00 | Buy | Jefferies |
| 1/28/2025 | $16.00 | Buy | Rodman & Renshaw |
| 7/23/2024 | $22.00 | Overweight | Piper Sandler |
| 4/3/2024 | $37.00 | Buy | Craig Hallum |
| 7/13/2023 | $35.00 | Outperform | Northland Capital |
4 - INDIVIOR PLC (0001625297) (Issuer)
4 - INDIVIOR PLC (0001625297) (Issuer)
4 - INDIVIOR PLC (0001625297) (Issuer)
Total Net Revenue Expected in the Range of $1,125 million to $1,195 millionTotal SUBLOCADE® Net Revenue Expected to be in the Range of $905 million to $945 millionNon-GAAP Operating Expenses Expected in the Range of $430 million to $450 millionAdjusted EBITDA Expected in the Range of $535 million to $575 million RICHMOND, Va., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Indivior PLC (NASDAQ:INDV) ("Indivior PLC" or the "Company") today announced its full-year 2026 financial guidance. "2025 was a transition year for Indivior in which we established the Indivior Action Agenda and completed Phase I – Generate Momentum – by growing U.S. SUBLOCADE net revenue, simplifying the organization and transform
RICHMOND, Va., Dec. 22, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) ("Indivior PLC" or the "Company") today announced that it will be added to the S&P SmallCap 600® index, effective today. "Indivior's inclusion in the S&P SmallCap 600 index marks an important milestone for Indivior that further aligns our capital markets presence with our sharpened U.S. business profile," said Joe Ciaffoni, Chief Executive Officer. "We are committed to growing SUBLOCADE®, our number one prescribed, first-in-class long-acting injectable treatment for moderate to severe opioid use disorder,
Both monthly maintenance doses (100 mg and 300 mg) improved opioid abstinence and were well-tolerated with no new safety signals identified.Post-hoc analyses indicated the 300-mg monthly maintenance dose performed significantly better than the 100-mg monthly dose in participants reporting high-frequency fentanyl use.RICHMOND, Va., Dec. 17, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today announced results from a randomized, double-blind clinical trial published in JAMA Network Open. The study found that both the 100-mg and 300-mg monthly maintenance doses of SUBLOCADE® (extended-release buprenorphine) rapidly reduced opioid use and improved opioid abstinence and were well tolerated, wit
4 - INDIVIOR PLC (0001625297) (Issuer)
4 - INDIVIOR PLC (0001625297) (Issuer)
4 - INDIVIOR PLC (0001625297) (Issuer)
8-K - INDIVIOR PLC (0001625297) (Filer)
SCHEDULE 13G - INDIVIOR PLC (0001625297) (Subject)
8-K - INDIVIOR PLC (0001625297) (Filer)
H.C. Wainwright initiated coverage of Indivior with a rating of Buy and set a new price target of $27.00
Jefferies resumed coverage of Indivior with a rating of Buy and set a new price target of $20.00
Rodman & Renshaw initiated coverage of Indivior with a rating of Buy and set a new price target of $16.00
Q3'25 Total Net Revenue of $314m, up 2% YOY; Q3'25 SUBLOCADE® Net Revenue of $219m, up 15% YOYAnnounces the Optimization of Rest of World (ROW) Business Discontinued the Sales and Marketing Support of OPVEE®Expect Annual Operating Expense Savings of at Least $150m in 2026On Track to Enter Phase II of the Indivior Action Agenda — Accelerate — January 1, 2026Conference Call Scheduled for Today at 8:00 A.M. EasternRICHMOND, Va., Oct. 30, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today reported its financial results for the third quarter ended September 30, 2025, and provided a business update.
RICHMOND, Va., Oct. 16, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today announced that it will report its third quarter 2025 financial results on Thursday, October 30, 2025, at 7:00 a.m. U.S. ET. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. ET. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begi
Q2'25 Total Net Revenue of $302m; Q2'25 SUBLOCADE® Net Revenue of $209m, up 9% Year-over-YearIndivior Action Agenda Underway to Strengthen Business and Generate Operational Momentum Conference Call Scheduled for Today at 8:00 A.M. EDTRICHMOND, Va., July 31, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today reported its financial results for the second quarter ended June 30, 2025, and provided a business update. "SUBLOCADE® net revenue and pricing stability in SUBOXONE® Film in the U.S. drove solid results in the second quarter, leading us to raise our 2025 financial guidan
SC 13G - INDIVIOR PLC (0001625297) (Subject)
SC 13G/A - INDIVIOR PLC (0001625297) (Subject)
SC 13D/A - INDIVIOR PLC (0001625297) (Subject)
NEW YORK, Dec. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 22, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 22, 2025 S&P 500 Addition CRH CRH Mat
RICHMOND, Va., July 8, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 2025. Vanessa is a seasoned corporate affairs leader with extensive experience in the biopharmaceutical industry, and will be responsible for Corporate Communications, Government Affairs, Policy and Advocacy at Indivior. "We are excited to welcome Vanessa to the Indivior team," said Joe Ciaffoni, Chief Executive Officer. "Vanessa has an impressive track record of aligning teams to pr
RICHMOND, Va., June 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of Directors as an Independent Non-Executive Director, effective July 1, 2025. Mr. Kingsley was appointed pursuant to Indivior's relationship agreement with affiliates of Oaktree Capital Management, L.P., who supported his appointment. Tony Kingsley is an accomplished biopharmaceutical executive with a distinguished track record of building and leading organizations across multiple scientific disciplines, therapeutic areas, and stages of